Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

A Pilot Study to Evaluate the Benefits of Phytocannabinoids for the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy

Award Number: R21CA260447
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/23/2022
PERIOD OF PERFORMANCE END DATE: 08/31/2026

Group Awards By:

View Award Description

A Pilot Study to Evaluate the Benefits of Phytocannabinoids for the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy - Project Summary Over 15 million cancer survivors live in the US, but unfortunately a large proportion of these patients experience long-term side effects from their treatments. This includes neuropathy, which is typically characterized by abnormal symptoms in the extremities including tingling, numbness, pain, or burning. When severe and chronic, neuropathy can interfere with all aspects of a patient’s life, diminishing their quality of life. Unfortunately for these patients, no therapy has been successful in helping patients entirely eliminate symptoms. With over 30 states legally providing medical cannabis, it has become increasing popular among cancer patients. However, the cancer community has very little data in which to guide patients about its use. By evaluating cannabis’s effect on neuropathy, we will be able to address this important gap in knowledge. Two important compounds found in medical cannabis are cannabidiol (CBD) and tetrahydrocannabinol (THC). This clinical trial will randomize breast and colon cancer survivors with chronic chemotherapy-induced peripheral neuropathy to two kinds of medical cannabis – CBD versus CBD+THC. Patients will be randomized to CBD, CBD+THC, or placebo and will be treated for 8 weeks. The results of this research are highly relevant to cancer survivors as a whole because the findings could be potentially applied to other cancer related pain syndromes. The data generated from this pilot study will provide important preliminary information needed to properly design a larger randomized clinical trial to evaluate the efficacy of cannabis for the treatment of CIPN. By helping patients reduce the symptoms of CIPN, we will help improve their quality of life, their ability to return to work, and their capacity to maintain an active lifestyle, which has increasingly been shown to help reduce the recurrence of cancer.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $0 )
2025	2022	BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE	1500 DUARTE RD	DUARTE	CA	91010	LOS ANGELES	USA	Cancer Treatment Research	000	1	12/19/2024	NEW	$0
2025	2022	BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE	1500 DUARTE RD	DUARTE	CA	91010	LOS ANGELES	USA	Cancer Treatment Research	001	1	9/18/2025	NEW	$0
														Subtotal = $0

Issue Date FY: 2022 ( Subtotal = $452,540 )
2022	2022	BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE	1500 DUARTE RD	DUARTE	CA	91010	LOS ANGELES	USA	Cancer Treatment Research	000	1	9/22/2022	NEW	$452,540
														Subtotal = $452,540

Grand Total All Awards = $452,540

Top

All Categories

About

Search

Reports

Data Submission

Award Information

A Pilot Study to Evaluate the Benefits of Phytocannabinoids for the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy

Award Number: R21CA260447

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/23/2022

PERIOD OF PERFORMANCE END DATE: 08/31/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer